QDEL

21.01

-1.5%↓

NERV

4.3

+5.91%↑

LSTA.US

2.02

-4.72%↓

QDEL

21.01

-1.5%↓

NERV

4.3

+5.91%↑

LSTA.US

2.02

-4.72%↓

QDEL

21.01

-1.5%↓

NERV

4.3

+5.91%↑

LSTA.US

2.02

-4.72%↓

QDEL

21.01

-1.5%↓

NERV

4.3

+5.91%↑

LSTA.US

2.02

-4.72%↓

QDEL

21.01

-1.5%↓

NERV

4.3

+5.91%↑

LSTA.US

2.02

-4.72%↓

Home・Aktien・Pharming Group NV

P
Pharming Group NV

Open

1.372 -4.52

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.349

Max

1.437

Schlüsselkennzahlen
By Trading Economics
Einkommen	2.9M 7.5M
Verkäufe	4.1M 97M
EPS	0.006
Gewinnspanne	7.758
Angestellte	404

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	379M 997M
Vorheriger Eröffnungskurs	5.89
Vorheriger Schlusskurs	1.372

Pharming Group NV Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

17. Nov. 2025, 18:59 UTC

Wichtige Markttreiber

Medicus Pharma Shares Rise After Filing of FDA Priority-Voucher Application

17. Nov. 2025, 23:40 UTC

Market Talk

Gold Consolidates Amid Mixed Signals -- Market Talk

17. Nov. 2025, 23:34 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

17. Nov. 2025, 22:58 UTC

Market Talk

RBA's Easing Cycle Is Done, TD Securities Says -- Market Talk

17. Nov. 2025, 22:46 UTC

Market Talk

Risk Assets Set to Have a Strong 2026 -- Market Talk

17. Nov. 2025, 22:06 UTC

Akquisitionen, Fusionen, Übernahmen

Constellation Software's Harris Operating Group Completes Agreement To Acquire TECVIA Holding GmbH >CSU.T

17. Nov. 2025, 22:02 UTC

Ergebnisse

Trip.com Group 3Q Rev $2.6B >TCOM

17. Nov. 2025, 22:02 UTC

Ergebnisse

Trip.com Group 3Q Adj EPS $3.87 >TCOM

17. Nov. 2025, 22:02 UTC

Ergebnisse

Trip.com Group 3Q EPS $4.02 >TCOM

17. Nov. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17. Nov. 2025, 21:40 UTC

Ergebnisse

James Hardie Industries 2Q Adj EPS 26c >JHX

17. Nov. 2025, 21:40 UTC

Ergebnisse

James Hardie Industries 2Q Loss/Shr 10c >JHX

17. Nov. 2025, 21:39 UTC

Ergebnisse

James Hardie Industries 2Q Sales $1.29B >JHX

17. Nov. 2025, 21:38 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17. Nov. 2025, 21:38 UTC

Ergebnisse

XPeng Earnings Beat Wall Street Estimates. Why the Stock Is Falling. -- Barrons.com

17. Nov. 2025, 21:10 UTC

Ergebnisse

XP Inc. 3Q EPS BRL2.47 >XP

17. Nov. 2025, 21:10 UTC

Ergebnisse

XP Inc. 3Q Rev BRL4.67B >XP

17. Nov. 2025, 20:20 UTC

Market Talk

U.S. Natural Gas Retreats on Milder Weather Outlook -- Market Talk

17. Nov. 2025, 20:12 UTC

Market Talk

Easing Underlying Inflation in Canada Seen Leaving Door Open to Rate Cuts Next Year -- Market Talk

17. Nov. 2025, 20:12 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. Nov. 2025, 20:09 UTC

Market Talk

Latest Canadian Inflation Data Supports View BoC is Done Cutting Rates This Cycle -- Market Talk

17. Nov. 2025, 19:29 UTC

Market Talk

Gold Slide Continues to Start Week -- Market Talk

17. Nov. 2025, 19:16 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17. Nov. 2025, 18:20 UTC

Akquisitionen, Fusionen, Übernahmen

Johnson & Johnson Will Buy Cancer Drugmaker Halda Therapeutics for $3.1 Billion -- Barrons.com

17. Nov. 2025, 16:45 UTC

Akquisitionen, Fusionen, Übernahmen

Oil Giant TotalEnergies Is Betting Big on Electricity -- Update

17. Nov. 2025, 16:16 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17. Nov. 2025, 16:15 UTC

Ergebnisse

Luckin, a Chinese Challenger to Starbucks, Aims to Return to U.S. Stock Market -- WSJ

17. Nov. 2025, 15:40 UTC

Akquisitionen, Fusionen, Übernahmen

Strategy Is in the Crosshairs of Crypto Investors. It Bought More Bitcoin Anyway. -- Barrons.com

17. Nov. 2025, 15:22 UTC

Akquisitionen, Fusionen, Übernahmen

Alphabet Stock Pops After Berkshire Takes Stake. Why Buffett Might Be Buying. -- Barrons.com

17. Nov. 2025, 15:19 UTC

Market Talk

Deutsche Bank's Strategic Plan Looks a Tad Underwhelming -- Market Talk

Peer-Vergleich

Kursveränderung

Pharming Group NV Prognose

Rating-Konsens

By TipRanks

0 ratings

Buy

Halten

Sell

Basierend auf 0 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Pharming Group NV – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.